David Ralston, MD
Pulmonary Disease · Grove City, OHNPI 1164408472
Payments from drug & device makers
Across 162 payments — averaging $195.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mylan Specialty L.p.$28K
- Boehringer Ingelheim$658
- Sanofi$626
- Jazz Pharmaceuticals Inc.$404
- GSK$269
- AstraZeneca$222
- plus $1K from 23 others
What the payments were for
- Consulting fees$7,28623%
- Speaking & faculty fees$20,15664%
- Travel & lodging$1,0003%
- Food & beverage$3,20210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mylan Specialty L.p. | 60 | $28,184 |
| Boehringer Ingelheim | 5 | $658 |
| Sanofi | 6 | $626 |
| Jazz Pharmaceuticals Inc. | 12 | $404 |
| GSK | 11 | $269 |
| AstraZeneca | 13 | $222 |
| Avadel CNS Pharmaceuticals, LLC | 3 | $197 |
| Grifols USA, LLC | 9 | $192 |
| Insmed, Inc. | 6 | $114 |
| Regeneron Healthcare Solutions, Inc. | 4 | $86 |
| Merck | 4 | $86 |
| Harmony Biosciences LLC | 3 | $61 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $51 |
| Actelion Pharmaceuticals US, Inc. | 2 | $51 |
| ZOLL Respicardia, Inc. | 1 | $51 |
| United Therapeutics Corporation | 2 | $50 |
| Paratek Pharmaceuticals, Inc. | 3 | $47 |
| Fisher & Paykel Healthcare Inc | 1 | $41 |
| Pfizer | 2 | $35 |
| Amgen | 2 | $33 |
| Idorsia Pharmaceuticals US Inc | 2 | $29 |
| Philips North America LLC | 2 | $29 |
| Resmed Corp | 1 | $26 |
| Baxter Healthcare | 1 | $25 |
| 3b Medical, Inc. | 1 | $19 |
| AbbVie | 1 | $18 |
| Covis Pharma GmbH | 1 | $15 |
| Gilead | 1 | $14 |
| Genentech USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$31,643 in reported general payments places this provider in the 80th percentile of 571 pulmonary disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 34 | $490,915 |
| WakixPitolisant Hcl | 11 | $141,855 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 111 | $122,836 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 71 | $66,235 |
| Dupixent SyringeDupilumab | 12 | $52,850 |
| Spiriva RespimatTiotropium Bromide | 35 | $30,368 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 32 | $28,512 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 34 | $28,221 |
| Breo ElliptaFluticasone/Vilanterol | 38 | $17,991 |
| Advair HfaFluticasone Propion/Salmeterol | 28 | $12,613 |
| SymbicortBudesonide/Formoterol Fumarate | 42 | $12,088 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 252 | $7,101 |
| Spiriva HandihalerTiotropium Bromide | 12 | $5,905 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 13 | $4,278 |
| Armodafinil | 28 | $3,998 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $658 | $549,795101 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta | $269 | $172,433195 claims |
| Harmony Biosciences LLCWakix | $61 | $141,85511 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $222 | $78,323113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 571 pulmonary disease providers in Ohio.
Other pulmonary disease in Grove City
- Bruce CorserCincinnati$8.2M
- Edward CordascoColumbus$8M
- Kristin HighlandCleveland$3.2M
- Brian ZenoColumbus$2.9M
- Jean ElwingCincinnati$2.4M
- Roy St JohnColumbus$1.9M
- Nishant GuptaCincinnati$1.5M
- Robert BaughmanCincinnati$1.1M
- Francis McCormackCincinnati$1.1M
- Leslie TolleCleveland$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.